CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
October 24 2014 - 10:09AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage
oncology company, today announced that it has closed an
underwritten public offering of 7,894,737 shares of common stock
and 1,973,684 warrants to purchase shares of common stock. For
every four shares of common stock sold, we issued to investors in
this offering one warrant to purchase a share of common stock. The
common stock and warrants were sold at a combined price of $0.76
and resulted in aggregate gross proceeds of $6 million, prior to
deducting underwriting commissions and offering expenses and
excluding the exercise of any warrants. The common stock and
warrants will separate immediately. The warrants are immediately
exercisable, expire October 11, 2018, have an exercise price of
$1.25 and trade on the NYSE MKT under the symbol “CVM WS”.
CEL-SCI intends to use the net proceeds of the offering for its
Phase III clinical trial, other research and development, and
general and administrative expenses.
Laidlaw & Company (UK) Ltd. is acting as the sole
book-running manager in this offering. Dawson James Securities,
Inc. is acting as a co-manager.
A shelf registration statement and accompanying base prospectus
on Form S-3 relating to the securities was filed with the
Securities and Exchange Commission and is effective. A final
prospectus supplement relating to the offering has been filed with
the SEC and is available on the SEC’s web site at
http://www.sec.gov. Copies of the final prospectus supplement
relating to the offering may be obtained from the offices of
Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th Floor, New
York, NY, 10036, telephone: 212-953-4900, or from the
above-mentioned SEC website.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About CEL-SCI Corporation
CEL-SCI Corporation is dedicated to research and development
directed at improving the treatment of cancer and other diseases by
utilizing the immune system, the body's natural defense system.
Safe Harbor Statement
When used in this release, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
include, without limitation, the company’s ability to complete the
proposed public offering of its common stock and warrants described
above. These forward-looking statements are based on our current
expectations and actual results could differ materially. Such
statements are subject to risks and uncertainties which could cause
actual results to differ materially from those projected, including
the risk factors set forth in CEL-SCI’s Form 10-K for the year
ended September 30, 2013 and other periodic reports filed with the
Securities and Exchange Commission. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events except as required by law.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024